Our favorite Journal has been around now for exactly 30 years. As editor, I’m extremely proud, and grateful to our diverse readers for the support, applause and, occasionally, well taken critics that constituted the success, and that has made us a well-informed, unbiased professional community that prioritize cancer prevention in the broadest sense.
Since the launch by Prof. Michael Hill, the submitted content has improved considerably and, as Prof. Carlo La Vecchia eloquently described in one of his most recent papers, we are winning the fight against cancer. Mortality indeed has dropped in developed countries 25 per cent compared to 30 years ago. It is the success of an enormous medical and industrial effort, and the Journal has assisted admirably in this challenging process.
We cannot allow to pass this anniversary without adequate celebrations. Editors, Publisher, and prominent ECP members wrote a short high-level paper about what they found the most noteworthy evolution during the past 30 years in their discipline. The papers will be published in volume 30 of the Journal during 2021. Content will also added to “collections” on the Journal’s website and some of these contributors will appear on video as well.
It might be expected that the Journal will stimulate decreasing cancer incidence and mortality even further in the future. What we did in the past and do now will be seen in the next generations in Western but even more in developing countries.
Prof. Jaak Ph. Janssens
Acibadem Sistina Hospital, April 4-5, 2020, Skopje.
This is an ECP supported meeting where ECP members are encouraged to participate. The conference is also accredited by the Medical Chamber of Macedonia. Lodging, registration, and local travel is free for ECP members. The official language is English. Presentations are 10 min.
A personalized approach in oncology takes gradually over from guidelines and relies on molecular biology of cancer cells. The information comes largely from tissue research. Therefore we, ECP and spin-off companies, concentrated on high quality tissues coming from patients (treatment related) or individuals (prevention) in the most comfortable and safe way.
But there is another factor, advances in molecular biology are much faster than in traditional, evidence based medicine. So, there is a rising conflict between laboratories and the hospital. This gap is addressed in our meetings were we join with interventionists (providing the tissue), pathologists (turn tissues into homogenates), molecular biologists (with an enormous array of services), oncologists that must indicate what they need and summarize to the patient the huge amount of molecular data, and health economics (because someone has to pay).
We had a first meeting on October 12, 2018 and this was very successful. We now like to continue and will broaden the scope to an international audience. Therefore we need people, research groups etc. to join us in the planning. Maybe you are interested?
If so, tell email@example.com
After a minor drop in recent years, the IF of the European Journal of Cancer Prevention remains on the rise. A combined achievement of authors, reviewers, and the editorial staff. Focus on “cancer” and “prevention” with the latest research technologies seems to generate high interest from the many readers.
Again an extremely successful meeting of the SToP group at the National Cancer Institute in Rockville (USA) on May 21 & 22. New data on gastric cancer. Info.
From Disease, Prevention to Treatment – Population, Medicine and Society.
Travel grants for young scientists available.
October 2 – 5, 2018.
All presentations from the November 2017 ECP Breast Cancer Prevention meeting as on the website of ThinkPink https://www.think-pink.be/en/ .
Please see the latest version of the ECP congress scientific program and registration:
For info on registration by groups: firstname.lastname@example.org
As the meeting in Antwerp is getting closer, we warmly invite you to join us. Please find the newest information here.